Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tazemetostat - Epizyme

Next Previous
X
Search
Drug Profile

Tazemetostat - Epizyme

Alternative Names: Davico; E-7438; EPZ-6438; EZ-438; IPN-60200; Tavico; Tazemetostat hydrobromide - Epizyme; Tazestat - Epizyme; Tazverik; Zestastat - Epizyme

Latest Information Update: 09 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Epizyme
  • Developer Eisai Co Ltd; Epizyme; Genentech; HUTCHMED; Ipsen; National Cancer Institute (USA); Pfizer
  • Class Amides; Amines; Antineoplastics; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
  • Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors; SMARCA2 protein inhibitors; SMARCA4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Rhabdoid tumour; Mesothelioma; Chordoma; Follicular lymphoma; Soft tissue sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Follicular lymphoma; Sarcoma
  • Registered Non-Hodgkin's lymphoma
  • Phase II CNS cancer; Diffuse large B cell lymphoma; Histiocytosis; Lymphoma; Mesothelioma; Neurofibrosarcoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Rhabdoid tumour; Solid tumours; Synovial sarcoma; Uterine cancer
  • Phase I/II Bladder cancer; Non-small cell lung cancer
  • No development reported B-cell lymphoma; Mantle-cell lymphoma

Most Recent Events

  • 04 Jul 2024 Preregistration for Follicular lymphoma (Second-line therapy or greater) in China (PO)
  • 04 Jul 2024 National Medical Products Administration (NMPA) of China accepts NDA for tazemetostat for Follicular lymphoma (Second-line therapy or greater) for review
  • 31 May 2024 Efficacy and adverse events data from a phase-I/II clinical trials in Bladder cancer presented at 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top